Join our daily newsletter At The Bell to receive exclusive market insights
- Rhinomed’s (RNO) interim results for its trial on respiratory virus diagnosis reveal the Rhinoswab Junior is an “overwhelmingly preferred” solution
- The trial investigated the diagnosis of respiratory viruses in children using the Rhinoswab Junior compared to the standard of care swab
- The Rhinoswab Junior achieved comparable sensitivity to the standard swab, but a higher specificity, and detects all patients who presented with SARS-CoV-2
- An online survey after the trial showed that 82.2 per cent of children prefer the Rhinoswab Junior and 82 per cent of the nursing staff favour it during the sample collection process
- Rhinomed jumps 9.43 per cent, trading at 29 cents at 11:40 am AEDT
Rhinomed (RNO) has received interim results for its trial on diagnosis of respiratory virus in children using its Rhinoswab Junior product.
The “Rhinoswab for diagnosis of respiratory virus in children” trial was carried out by clinical scientists at the Murdoch Children’s Research Institute at the Melbourne Children Trials Centre.
The trial investigated the diagnosis of respiratory viruses in children using the Rhinoswab Junior. The device was design to collect a nasal sample from children without the discomfort and distress associated with the combined throat and deep nasal swabs.
Rhinoswab Junior is a smaller version of the original Rhinoswab device, with child friendly features built in to engage children during the sampling process.
The trial recruited 254 symptomatic children, aged between four and eighteen who presented at the Respiratory infection Clinic at The Royal Children’s Hospital Melbourne.
Each child was sampled with the standard of care combined nose and throat swab and the Rhinoswab Junior. The samples were then assessed to compare the performance of Rhinoswab Junior with the current standard swab.
The Rhinoswab Junior achieved comparable sensitivity to the standard swab, but a higher specificity. It was also able to detect 100 per cent of the patients who presented with SARS-CoV-2.
An online survey after the trial showed that 82.2 per cent of children preferred the Rhinoswab Junior, 6.7 per cent had no preference, and 11.5 per cent preferred the standard swab.
Additionally, 79 per cent of parents preferred the Rhinoswab, while 82 per cent of the nursing staff preferred the use of the Rhinoswab in the sample collection process.
“These results confirm that not only is the Rhinoswab Junior comparable to the highly invasive gold standard nose and throat swab in terms of lab performance, it is overwhelmingly preferred by children, parents and nurses,” said Michael Johnson, CEO of Rhinomed.
The company said the results provide confidence that the Rhinoswab Junior can make a significant difference across the global testing market.
Rhinomed jumped 9.43 per cent, trading at 29 cents at 11:40 am AEDT.
